JP2024515828A5 - - Google Patents
Info
- Publication number
- JP2024515828A5 JP2024515828A5 JP2023566513A JP2023566513A JP2024515828A5 JP 2024515828 A5 JP2024515828 A5 JP 2024515828A5 JP 2023566513 A JP2023566513 A JP 2023566513A JP 2023566513 A JP2023566513 A JP 2023566513A JP 2024515828 A5 JP2024515828 A5 JP 2024515828A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- tautomer
- stereoisomer
- solvate
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181796P | 2021-04-29 | 2021-04-29 | |
| US63/181,796 | 2021-04-29 | ||
| US202163186739P | 2021-05-10 | 2021-05-10 | |
| US63/186,739 | 2021-05-10 | ||
| US202163273118P | 2021-10-28 | 2021-10-28 | |
| US63/273,118 | 2021-10-28 | ||
| US202263311781P | 2022-02-18 | 2022-02-18 | |
| US63/311,781 | 2022-02-18 | ||
| PCT/US2022/027120 WO2022232634A1 (en) | 2021-04-29 | 2022-04-29 | Deubiquitinase-targeting chimeras and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515828A JP2024515828A (ja) | 2024-04-10 |
| JP2024515828A5 true JP2024515828A5 (enExample) | 2025-05-12 |
Family
ID=81748638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566513A Pending JP2024515828A (ja) | 2021-04-29 | 2022-04-29 | デユビキチナーゼ標的化キメラ及び関連する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240252655A1 (enExample) |
| EP (1) | EP4329815A1 (enExample) |
| JP (1) | JP2024515828A (enExample) |
| KR (1) | KR20240004584A (enExample) |
| CN (1) | CN120225225A (enExample) |
| AU (1) | AU2022265718A1 (enExample) |
| BR (1) | BR112023022315A2 (enExample) |
| CA (1) | CA3216614A1 (enExample) |
| IL (1) | IL307863A (enExample) |
| MX (1) | MX2023012852A (enExample) |
| WO (1) | WO2022232634A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024220874A2 (en) * | 2023-04-21 | 2024-10-24 | Icahn School Of Medicine At Mount Sinai | Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs) |
| WO2024233280A1 (en) * | 2023-05-05 | 2024-11-14 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7 |
| WO2024264072A2 (en) * | 2023-06-23 | 2024-12-26 | Stablix, Inc. | Parp inhibitors |
| CN119350422B (zh) * | 2024-12-25 | 2025-04-04 | 中国药科大学 | 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008109031A (ru) | 2005-08-11 | 2009-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы муковисцидозного трансмембранного регулятора проводимости |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| PL2168966T3 (pl) | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| CN102743385B (zh) * | 2007-11-16 | 2014-09-17 | 沃泰克斯药物股份有限公司 | Atp结合盒转运蛋白的异喹啉调节剂 |
| US20110035601A1 (en) | 2007-12-21 | 2011-02-10 | University Of Virginia Patent Foundation | System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms |
| EP2303885B1 (en) | 2008-06-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Process for producing bicycloaniline derivatives |
| CZ2009620A3 (cs) | 2009-09-22 | 2011-04-06 | Ústav makromolekulární chemie AV CR, v.v.i. | Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2011133953A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| KR20150097660A (ko) | 2012-12-19 | 2015-08-26 | 노파르티스 아게 | Cftr 채널을 억제하기 위한 트리시클릭 화합물 |
| CA2895656A1 (en) | 2012-12-19 | 2014-06-26 | Novartis Ag | Tricyclic compounds as cftr inhibitors |
| WO2018037350A1 (en) | 2016-08-23 | 2018-03-01 | Laurus Labs Limited | Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof |
| CA3103205A1 (en) * | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting uchl5 |
| WO2020069105A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
| AU2020224327B2 (en) * | 2019-02-21 | 2022-09-29 | Entact Bio Limited | Survival-targeting chimeric ( SURTAC) molecules |
| EP4090371A4 (en) * | 2020-01-14 | 2024-04-03 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES |
-
2022
- 2022-04-29 CA CA3216614A patent/CA3216614A1/en active Pending
- 2022-04-29 AU AU2022265718A patent/AU2022265718A1/en active Pending
- 2022-04-29 KR KR1020237040245A patent/KR20240004584A/ko active Pending
- 2022-04-29 IL IL307863A patent/IL307863A/en unknown
- 2022-04-29 BR BR112023022315A patent/BR112023022315A2/pt unknown
- 2022-04-29 US US18/288,550 patent/US20240252655A1/en active Pending
- 2022-04-29 WO PCT/US2022/027120 patent/WO2022232634A1/en not_active Ceased
- 2022-04-29 JP JP2023566513A patent/JP2024515828A/ja active Pending
- 2022-04-29 EP EP22724358.1A patent/EP4329815A1/en active Pending
- 2022-04-29 CN CN202280032073.1A patent/CN120225225A/zh active Pending
- 2022-04-29 MX MX2023012852A patent/MX2023012852A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faridoon et al. | An update on the discovery and development of reversible covalent inhibitors | |
| Tu et al. | Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma | |
| Han et al. | Discovery of selective small molecule degraders of BRAF-V600E | |
| JP7600396B2 (ja) | 化合物及びその使用 | |
| US20220119378A1 (en) | Compounds and uses thereof | |
| US20210292298A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| EP4132529A1 (en) | Compounds and uses thereof | |
| US20160237082A1 (en) | Deubiquitinase inhibitors and methods for use of the same | |
| CN113207291A (zh) | 2-(2-丙烯酰基-2,6-二氮杂螺[3.4]辛-6-基)-6-(1h-吲唑-4-基)苄腈衍生物及相关化合物作为用于抑制肿瘤转移的g12c突变kras蛋白的抑制剂 | |
| CN112584833A (zh) | 杂环螺化合物及其用于治疗癌症的使用方法 | |
| US10562864B2 (en) | Chemical modulators of immune checkpoints and therapeutic use | |
| EP3350181B1 (en) | Her3 ligands and uses thereof | |
| KR20150093695A (ko) | Malt1의 소분자 억제제 | |
| KR20260047240A (ko) | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 | |
| US11857550B2 (en) | Benzathine analogs | |
| US9403797B2 (en) | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | |
| EA001794B1 (ru) | Гетероциклические азагексановые производные с антивирусным действием | |
| CA2870837A1 (en) | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof | |
| Sun et al. | Discovery of novel HDAC3 inhibitors with PD-L1 downregulating/degrading and antitumor immune effects | |
| KR20060101761A (ko) | Ｋｉｔ 돌연변이형에 대한 저해제 | |
| CN120225225A (zh) | 去泛素化酶靶向性嵌合体及相关方法 | |
| Çıkla et al. | Synthesis and evaluation of antiviral, antitubercular and anticancer activities of some novel thioureas derived from 4-aminobenzohydrazide hydrazones | |
| WO2022159650A1 (en) | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2 | |
| Liu et al. | Synthesis and biopharmaceutical studies of JLTN as potential dasatinib prodrug | |
| EP1892245B1 (en) | Antineoplastic compounds and pharmaceutical compositions thereof |